3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
104
Endocrine
40
Thoracic
16
Gastrointestinal
13
Breast
10
Sarcoma
8
Genitourinary
7
Dermatologic
7
Gynecologic
6
CNS
6
Lymphoid
4
Other solid neoplasm
2
NET
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myeloid, Acute
772
Leukemia
596
Leukemia, Lymphocytic, Chronic, B-Cell
535
Precursor Cell Lymphoblastic Leukemia-Lymphoma
485
Myelodysplastic Syndromes
408
Lymphoma, Non-Hodgkin
265
Lymphoma
265
Hematologic Neoplasms
251
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
232
Multiple Myeloma
199
Hodgkin Disease
193
Lymphoma, Follicular
181
Lymphoma, Mantle-Cell
179
Lymphoma, B-Cell, Marginal Zone
156
Lymphoma, Large B-Cell, Diffuse
155
Burkitt Lymphoma
155
Recurrence
149
Leukemia, Myelomonocytic, Chronic
139
Congenital Abnormalities
131
Myeloproliferative Disorders
122
Waldenstrom Macroglobulinemia
106
Neoplasms
97
Leukemia, Myeloid, Chronic-Phase
97
Lymphoma, Large-Cell, Immunoblastic
91
Primary Myelofibrosis
88
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
81
Blast Crisis
80
Leukemia, Myeloid, Accelerated Phase
74
Anemia, Refractory, with Excess of Blasts
72
Lymphoma, T-Cell, Cutaneous
68
Interventions
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Thyroid Neoplasms
×
Other hematologic neoplasm
×
Clear all
NCT01831726
2017-03-20
SIGNATURE
Novartis
Phase 2
Completed
80 enrolled
9 charts